Fueled by remarkable breakthroughs in vaccines and new therapies, a greater understanding and treatment of overall health, and new ways of deploying data to improve patient care, there are now a host of new, dynamic solutions to some of the world’s biggest health challenges. But there is also a sense of unevenness and inconsistency when it comes to opportunities and developments in the space.
CNBC’s Healthy Returns convenes the sharpest minds, bold pioneers and visionary leaders in the health care industry on what they see ahead for treatments and innovations, what’s working, what needs to improve, and what’s on the horizon that will shape health care for the future.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
Rosalind (Roz) Brewer joined Walgreens Boots Alliance as Chief Executive Officer in March 2021. She also is a Director on WBA’s Board. Ms. Brewer most recently served as Chief Operating Officer and Group President at Starbucks from October 2017 to January 2021. Prior to Starbucks, she served as President and Chief Executive Officer of Sam’s Club, a membership-only retail warehouse club and division of Walmart, Inc., from February 2012 to February 2017. Ms. Brewer previously held several executive leadership positions with Walmart beginning in 2006.
Prior to joining Walmart, she served as President of Global Nonwovens Division for Kimberly-Clark Corporation, a global health and hygiene products company, from 2004 to 2006, and held various management positions at Kimberly-Clark beginning in 1984.
She currently serves as the Chairperson of the Board of Trustees for Spelman College, where she did her undergraduate work. Ms. Brewer also is a Board Member of VillageMD, World Business Chicago, Business Roundtable and the Smithsonian’s National Museum of African-American History and Culture. Ms. Brewer formerly served on the Board of Directors for Starbucks, Amazon, Lockheed Martin Corporation and Molson Coors Brewing Company. She is currently ranked #6 on Fortune’s 50 Most Powerful Women in Business and was named one of the 25 most influential women by the Financial Times in 2021.
Joaquin Duato is the Chief Executive Officer of Johnson & Johnson and serves on its Board of Directors. As CEO of the world’s largest healthcare company, Joaquin leads a global workforce of 135,000 employees in developing and delivering transformational and innovative healthcare solutions in Pharmaceuticals, MedTech, and Consumer Health.
From his early days in Spain, Joaquin found inspiration by focusing on how healthcare improved patients’ lives. Over the course of three decades with the company, he developed a deep understanding of what’s possible at Johnson & Johnson by working in all business sectors and across multiple geographies and functions. Before being named CEO, Joaquin served as the Vice Chairman of the Executive Committee, where he provided strategic direction for the Pharmaceutical and Consumer Health sectors and oversaw both Information Technology and the Global Supply Chain.
Joaquin’s many accomplishments include driving the transformation of the company’s pharmaceutical business into a global powerhouse by refocusing strategy and investment around core therapeutic areas and areas of greatest unmet need during his tenure as the sector’s Worldwide Chairman. More recently, he oversaw the company’s rapid response to the COVID-19 pandemic and drove coordination of global initiatives to safeguard the health of employees and ensure business and supply chain continuity, so the company’s life-saving medicines and products reached patients and communities in need.
A believer in the power of technology to accelerate progress in healthcare, Joaquin is leading Johnson & Johnson to harness data science and intelligent automation for insight generation so that teams work as a united front, with expertise and purpose, to solve the world’s toughest health challenges.
A dual citizen of Spain and the United States, Joaquin’s international perspective gives him a deep appreciation of diversity in all its forms. He is committed to building an inclusive workforce that reflects the patients J&J serves, evidenced by nearly a decade acting as Executive Sponsor for the African Ancestry Leadership Council ERG.
Joaquin earned an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona. He lives in Pennsylvania with his wife and two college-aged children.
Dr. Brown graduated from Yale College, where she majored in molecular biophysics and biochemistry. She earned her medical degree from Harvard University. She completed internship and residency programs in medicine at Vanderbilt University, where she also did a fellowship in clinical pharmacology. Dr. Brown joined the faculty of Vanderbilt in 1992 and held a number of leadership positions, serving as chief of the Division of Clinical Pharmacology, associate dean for clinical and translational scientist development, and Robert H. Williams professor before becoming the Hugh J. Morgan Chair of Medicine and physician-in-chief of Vanderbilt University Hospital in 2010.
In 2020, she became Jean and David W. Wallace Dean of Medicine and C.N.H. Long Professor of Internal Medicine at Yale School of Medicine. Dr. Brown has long been committed to medical education and mentorship. At Vanderbilt, she established the Elliot Newman Society to support the development of physician-scientists and co-founded the Vanderbilt Master of Science in Clinical Investigation program. Her research has defined the molecular mechanisms through which commonly prescribed blood pressure and diabetes drugs affect the risk of cardiovascular and kidney disease. In her clinical practice, she has treated patients with resistant and secondary forms of hypertension. Dr. Brown has served as a member of the NIH National Advisory Research Resources Council and the National Heart, Lung, and Blood Advisory Council. She was president of the Association of Professors of Medicine. In 2019, she was elected a Master of the American College of Physicians.Her numerous awards include election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. She is a member of the American Association of Arts and Sciences.
World-renowned cardiologist Dr. Henry Ting joined Delta Air Lines in 2021 as the global brand’s Chief Health Officer – a first for a U.S. airline. In his most recent role as Mayo Clinic’s enterprise Chief Value Officer, Dr. Ting became familiar with Delta both as a long-time Medallion customer and, more recently, as a primary COVID-19 advisor who has helped shape Delta’s response since the early days of the pandemic.
From employee testing and cleanliness strategies to operational tactics that reduce the transmission of the virus, Dr. Ting has been a key voice in the health and wellness decisions that have helped Delta strengthen the people-first approach we were known for even prior to the pandemic. As part of the Delta team, Dr. Ting is building on this work to help Delta navigate the pandemic and emerge stronger and better prepared for the future.
Working collaboratively with groups across the airline, Dr. Ting leads Delta in reimagining our approach to health and well-being, utilizing new technologies, artificial intelligence, advanced analytics and innovative partnerships.
In addition to his role at Delta, Dr. Ting retains his title as Professor Emeritus at Mayo Clinic.
Before joining Delta, Dr. Ting served in multiple leadership roles at Mayo Clinic including enterprise Chief Value Officer, clinical practice Chair of the Department of Cardiology and Associate Dean. He also served as S.V.P. and Chief Quality Officer at New York Presbyterian Hospital.
Dr. Ting’s academic focus includes health services research, outcomes research and implementation science. He has lectured worldwide and authored over 200 journal articles, book chapters and publications. In addition, he has served on committees and boards for the U.S. Department of Health and Human Services, U.S. Agency for Healthcare Research and Quality, National Quality Forum and U.S. News & World Report advisory council.
Dr. Ting received his bachelor’s degree in chemistry from Cornell University, Doctorate of Medicine from Harvard Medical School and master’s degree in business administration from the University of St. Thomas.
*Agenda subject to change
11:00am ET
Tyler Mathisen, CNBC “Power Lunch” Co-Anchor & Vice President, Events Strategy
In his first sit-down interview, Johnson & Johnson’s new CEO Joaquin Duato shares his vision for the future of the world’s largest healthcare company and how he plans to continue to drive growth across the business.
Joaquin Duato, Johnson & Johnson Chief Executive Officer
Interviewer: Meg Tirrell, CNBC Health & Science Reporter
Last year was a banner year for digital health with nearly $60 billion invested into the sector globally. And VCs remain bullish on the long-term potential for health tech across multiple disruptive sectors including health IT, biopharma, medical devices and telehealth. Two leading health investors share their top tech picks that will transform health care in 2022 and beyond.
Deena Shakir, Lux Capital Partner
Mohamad Makhzoumi, NEA Managing General Partner, Healthcare
Moderator: Melissa Lee, CNBC “Fast Money” & “Options Action” Host
The global RNAi therapeutic market is expected to top $11. 5 billion by 2027, on the potential to cure a wide range of severe and debilitating diseases. Dr. Greenstreet walks us through the R&D breakthroughs and 2022 pipeline for this Nobel-winning “gene-silencing” technology.
Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals Chief Executive Officer
Interviewer: Meg Tirrell, CNBC Health & Science Reporter
The nature of the global airline business keeps Delta’s front-line teams (flight attendants, gate agents, customer service reps, maintenance crews, pilots) busy round the clock, 24/7. Taking care of the team’s physical health and mental wellness is a priority of the carrier’s leadership strategy. By investing in employee resilience and wellbeing, they in turn are better able to deliver a positive and safer travel experience for all its passengers.
Dr. Henry Ting, Delta Air Lines Chief Health Officer
Interviewer: Phil LeBeau, CNBC Auto & Airline Industry Reporter
12:30 pm
Join the conversation on camera for these interactive, topic-based sessions led by industry leaders. Share your thoughts, ask questions, exchange ideas and network with event speakers and your peers.
The workplace has become more instrumental in employee health and wellness than ever before. Beyond standard benefits, employers have become a resource for mental health initiatives, testing, preventative care and much more, but as workers have shorter tenures at jobs today than in the past, could these initiatives have less staying power? Share your thoughts, ask questions, exchange ideas and network with members of our CNBC Workforce Executive Council and your peers.
Featured Guests:
Laura Birk, Barilla America Vice President, Human Resources
Kathleen Carroll, Grainger Senior Vice President and Chief Human Resources Officer
Jim Dunn, Atrium Health Chief People and Culture Officer
Moderator: Sharon Epperson, CNBC Personal Finance Correspondent
Big data and AI have unleashed a deluge of health tech start-ups and innovative ideas from mainstay companies. But for every great gadget, there’s often a flop. How do investors and prospective users know what’s a breakthrough and what isn’t; how concerned should users be about privacy and what’s the long-term outlook for the health care and technology industries working together? More mergers? New companies? Share your thoughts, ask questions, exchange ideas and network with members of our CNBC Technology Executive Council and your peers.
Featured Guests:
Rajeev Ronanki, Anthem President of Digital Platforms
Michael Saad, University of Tennessee Medical Center SVP and CIO
Moderator: Deirdre Bosa, “TechCheck” Co-Anchor
1:30 pm
Since its launch a mere two years ago, EQRx’s bold – some say audacious – goal to develop and deliver new medicines at radically lower prices continues to shake up the drug market. A simple solution to a complex problem, according to backers like Google Ventures and Andreessen Horowitz, who are betting on a fast-moving pipeline, partnerships and lower costs to radically remake medicine for all.
Melanie Nallicheri, EQRx Chief Executive Officer
Interviewer: Tyler Mathisen, CNBC “Power Lunch” Co-Anchor & Vice President, Events Strategy
Two renowned nonprofit medical leaders and health equity advocates on the lessons learned from the pandemic, and ways to solve the health disparities that continue to divide our nation.
Dr. Nancy Brown, Yale School of Medicine Dean
Dr. Gary Désir, Yale School of Medicine Department of Internal Medicine Chair
Moderator: Contessa Brewer, CNBC Correspondent
After what has undoubtedly been a very rocky 12 months for biotech, is the sector ripe for a comeback? Biotech investor and Harvard-trained medical doctor, Dr. Christiana Bardon thinks advances in gene therapies, robust drug pipelines and an improving regulatory landscape will be key industry drivers for the road ahead.
Dr. Christiana Bardon, MPM Capital Co-Managing Partner
Interviewer: Leslie Picker, CNBC Finance and Investing Reporter
Major drugstore chains like Walgreens served as trusted health care hubs during the Covid-19 pandemic. It’s where Americans turned for testing, vaccinations, and hard to find goods close to home. The crisis came just as Walgreens looked to transform itself into a health care destination in the community, with digital and in-person primary care through VillageMD, and pharmacists playing a central role helping customers manage their health. In a rare interview, one year into her tenure, CEO Roz Brewer shares her vision for how Walgreens can bridge the care gap for patients and their caregivers in our fragmented health system.
Rosalind Brewer, Walgreens Boots Alliance Chief Executive Officer
Interviewer: Bertha Coombs, CNBC Reporter
Registration for the Healthy Returns Summit is now closed. To view all videos on demand, please go to cnbc.com/healthy-returns. Please email events@cnbc.com for any questions.
Medallia is the pioneer and market leader in Experience Management. Medallia’s award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens. Using Medallia customers can reduce churn, turn detractors into promoters and buyers and create in-the-moment cross-sell and up-sell opportunities, enabling clear returns on investment. www.medallia.com.
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Indigo. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Dr. Elaine Batchlor is the chief executive officer of Martin Luther King, Jr. Community Hospital, which opened in 2015. Dr. Batchlor was the driving force behind the effort to open the new, state-of-the-art, community-oriented, safety-net hospital providing compassionate, quality care and improving the health of the South Los Angeles community.
Throughout her career, Dr. Batchlor’s number one priority has been to improve access and quality of care for underserved communities utilizing innovative and collaborative approaches. Her work to increase access for underserved populations has been recognized as an example of leading best practices and adopted throughout California.
Before assuming the helm of Martin Luther King, Jr. Community Hospital, Dr. Batchlor served on the executive leadership team of L.A. Care Health Plan, the nation’s largest public health plan. As chief medical officer, she was instrumental in developing a care delivery model that expanded access and resources to more than a million individuals throughout the county.
She spearheaded provider use of information technology and telemedicine to improve access and quality of care for Los Angeles County’s Medi-Cal (Medicaid) population. Under her leadership, L.A. Care established the Health Information Technology Extension Center, becoming the second health plan in the nation to operate a Regional Extension Center to help safety-net providers adopt and use electronic health records. She implemented eConsult, an innovative electronic physician-to-specialist consultation and referral system, for Los Angeles County community health centers and the Los Angeles County Department of Health Services.
Prior to L.A. Care, Dr. Batchlor served in leadership positions at the California HealthCare Foundation, the Los Angeles County Department of Health Services, Prudential Health Care, and Ross Loos Medical Group. Early in her career she served as a clinical instructor at the UCLA School of Medicine.
Dr. Batchlor is an active community volunteer, serving on multiple community and healthcare boards. She has a particular interest in mentoring youth. She regularly meets with students, from high school through professional school, who are interested in careers in healthcare. Formerly, she served on advisory boards for the UCLA Fielding School of Public Health, the UCLA National Clinical Scholars, and the UCLA Academic Advancement Program Advisory Council. Recently, she was elected to the National Academy of Medicine, an academy committed to the health for all by advancing science, accelerating health equity, and providing independent, authoritative, and trusted advice nationally and globally. A Harvard alumna, Dr. Batchlor serves as an interviewer for Harvard College applicants and as a liaison to a local high school.
She served as the past chair and is currently on the board of the Integrated Healthcare Association. She is a member of the Board of Trustees of the California Association of Hospitals and Health Systems, the boards of directors of the Healthcare Quality Institute and California Health and Wellness, and the editorial board of Health Affairs, the leading peer-reviewed journal of health policy thought and research.
Dr. Batchlor received a Bachelor of Arts degree from Harvard University, a Master of Public Health degree from the University of California, Los Angeles, and a Doctorate in Medicine degree from Case Western Reserve University. She completed internship, residency, and fellowship training in internal medicine and rheumatology at Harbor-UCLA Medical Center and is board-certified in both specialties.
She is married to a lawyer who has spent his career representing indigent clients, currently working for the Los Angeles County Public Defender’s Office. The couple has twin boys.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.